

## Genetics and Genomics Seminar Series



**André Leier, PhD**

**Assistant Professor, Department of Genetics UAB**

### **“Therapeutic Ribozyme Development: Targeting *JAK2*, *CFTR* and *NF1* mRNA”**

Friday, December 3, 2021

12:00pm

**Register in advance for this meeting:**

[https://uab.zoom.us/meeting/register/tZMudeqrrz0tEtTWLOgQSx8xQnwo2\\_g1etiA](https://uab.zoom.us/meeting/register/tZMudeqrrz0tEtTWLOgQSx8xQnwo2_g1etiA)

Target Audience: UAB Broader Genetics Community

Disclosures and acknowledgements:

- Dr. André Leier has no actual or potential conflict of interest in relation to this program/presentation.
- The following planners, speakers, moderators, and/or panelists of this CE activity have no relevant financial relationships with commercial interests to disclose: Lizhong Wang, PhD; Runhua Liu; PhD

There is no commercial support for this session

Objectives: After attending this session, participants should be able to understand:

1. Trans-splicing group I intron ribozymes and their therapeutic potential.
2. Myeloproliferative neoplasms (MPNs) and their most common driver JAK2-V617F.
3. Efforts towards the development of a ribozyme-based curative therapy for JAK2-V617F-positive MPNs.
4. Ongoing efforts to optimize ribozymes for the repair of messenger RNAs applied to the genetic diseases Neurofibromatosis Type I and Cystic Fibrosis.

Sponsored for CME Credit by UAB Division of CME

The University of Alabama School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Alabama School of Medicine designates this Regularly Scheduled Series session for a maximum of 1 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The University of Alabama School of Medicine is an equal opportunity/affirmative action institution.